Department of Gynecology, Gunma Prefectural Cancer Center, Ota, Japan.
Department of Obstetrics and Gynecology, Takasaki General Medical Center, Takasaki, Japan.
BMC Womens Health. 2023 Apr 20;23(1):186. doi: 10.1186/s12905-023-02371-7.
In Japan, 8000 women were newly diagnosed with cervical cancer in 2018. The healthcare insurance policy in Japan allows physicians to utilize vaginal volt cytology tests and serum biomarker measurement at every visit and imaging analysis at an adequate interval with screening for recurrence after initial treatment. However, the major surveillance guidelines published in the United States and European countries recommend focusing on pelvic examinations and symptom reviews to avoid unnecessary tests. This study aimed to reassess the benefits of standard surveillance methods adopted in this study by retrospective analysis.
From January 2009 to December 2015, the medical records of patients with recurrence who were initially diagnosed with International Federation of Gynecology and Obstetrics stage I-III cervical cancer were collected for this study. Clinicopathological data were statistically analyzed to identify significant factors. In the first 2 years, the patients underwent regular surveillance, including pelvic examination, serum tumor marker tests, vaginal vault cytology every 1-3 months, and imaging analysis at 6- to 12-month intervals. In the following 2 years, the patients received a regular check with the same methods every 4 months and an annual imaging analysis. Afterward, the patients had regular screening every 6 to 12 months.
In the study period, 84 of the 981 patients experienced recurrence, and 88.1% had an asymptomatic recurrence. The disease-free interval was not related to the recurrence site. In univariate analysis, primary treatment, recurrence site, and diagnostic method were significant factors for survival outcomes. In contrast, multivariate analysis indicated that only primary treatment was a significant factor. In patients with local recurrence, multivariate analysis demonstrated that radiation as salvage therapy was an independent predictive factor for overall survival after recurrence.
In this retrospective study, routine imaging analysis and serum biomarker measurement did not contribute to patient prognosis after recurrence. In contrast, vaginal vault cytology can improve survival after recurrence in some patients. Tailored surveillance methods based on individual disease conditions and treatment modalities can improve post-recurrent survival outcomes.
2018 年,日本有 8000 名女性被新诊断出患有宫颈癌。日本的医疗保险政策允许医生在每次就诊时进行阴道电压细胞学检查和血清生物标志物测量,并在适当的间隔内进行影像学分析,以对初始治疗后的复发进行筛查。然而,美国和欧洲国家发布的主要监测指南建议重点进行盆腔检查和症状回顾,以避免不必要的检查。本研究旨在通过回顾性分析重新评估本研究中采用的标准监测方法的益处。
本研究收集了 2009 年 1 月至 2015 年 12 月期间初次诊断为国际妇产科联合会(FIGO)I-III 期宫颈癌且复发的患者的病历资料。对临床病理数据进行了统计学分析,以确定显著因素。在前 2 年,患者接受了常规监测,包括盆腔检查、血清肿瘤标志物检测、阴道穹隆细胞学检查(每 1-3 个月进行一次)和 6-12 个月间隔的影像学分析。在接下来的 2 年中,患者每 4 个月接受相同方法的常规检查和每年的影像学分析。此后,患者每 6-12 个月进行常规筛查。
在研究期间,981 名患者中有 84 名出现复发,88.1%的患者为无症状复发。无疾病间隔与复发部位无关。单因素分析表明,主要治疗、复发部位和诊断方法是生存结果的显著因素。相比之下,多因素分析表明只有主要治疗是一个显著因素。对于局部复发患者,多因素分析表明,挽救性放疗是复发后总生存的独立预测因素。
在这项回顾性研究中,常规影像学分析和血清生物标志物测量对复发后患者的预后没有贡献。相比之下,阴道穹隆细胞学检查可以提高某些患者的复发后生存。基于个体疾病状况和治疗方式的个体化监测方法可以改善复发性生存结局。